Cargando…

Drug–Drug Interactions with the NS3/4A Protease Inhibitor Simeprevir

Simeprevir is an NS3/4A protease inhibitor approved for the treatment of hepatitis C infection, as a component of combination therapy. Simeprevir is metabolized by the cytochrome P450 (CYP) system, primarily CYP3A, and is a substrate for several drug transporters, including the organic anion transpo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ouwerkerk-Mahadevan, Sivi, Snoeys, Jan, Peeters, Monika, Beumont-Mauviel, Maria, Simion, Alexandru
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2015
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4756048/ https://www.ncbi.nlm.nih.gov/pubmed/26353895 http://dx.doi.org/10.1007/s40262-015-0314-y

Ejemplares similares

Evaluation of the Pharmacokinetics and Renal Excretion of Simeprevir in Subjects with Renal Impairment
por: Ouwerkerk-Mahadevan, Sivi, et al.
Publicado: (2015)

Clinical impact of pharmacokinetic interactions between the HCV protease inhibitor simeprevir and frequently used concomitant medications
por: Marra, Fiona, et al.
Publicado: (2018)

Physiologically‐based pharmacokinetic modeling for investigating the effect of simeprevir on concomitant drugs and an endogenous biomarker of OATP1B
por: Nakayama, Shinji, et al.
Publicado: (2023)

Fatigue during treatment for hepatitis C virus: results of self-reported fatigue severity in two Phase IIb studies of simeprevir treatment in patients with hepatitis C virus genotype 1 infection
por: Scott, Jane, et al.
Publicado: (2014)

The Molecular Basis of Drug Resistance against Hepatitis C Virus NS3/4A Protease Inhibitors
por: Romano, Keith P., et al.
Publicado: (2012)

Population Pharmacokinetic Analysis of Bedaquiline‐Clarithromycin for Dose Selection Against Pulmonary Nontuberculous Mycobacteria Based on a Phase 1, Randomized, Pharmacokinetic Study
por: Kurosawa, Ken, et al.
Publicado: (2021)

Photo-induced drug eruption in a patient on combination simeprevir/sofosbuvir for hepatitis C
por: Eyre, Zachary W., et al.
Publicado: (2016)

Repurposing the HCV NS3–4A protease drug boceprevir as COVID-19 therapeutics
por: Oerlemans, Rick, et al.
Publicado: (2020)

Application of different spectrophotometric methods for quantitative analysis of direct acting antiviral drugs simeprevir and sofosbuvir
por: Ramzy, Sherif, et al.
Publicado: (2022)

Evaluating Andrographolide as a Potent Inhibitor of NS3-4A Protease and Its Drug-Resistant Mutants Using In Silico Approaches
por: Chandramohan, Vivek, et al.
Publicado: (2015)

Avoiding Drug Resistance by Substrate Envelope-Guided Design: Toward Potent and Robust HCV NS3/4A Protease Inhibitors
por: Matthew, Ashley N., et al.
Publicado: (2020)

Allosteric Inhibitors of Zika Virus NS2B-NS3 Protease Targeting Protease in “Super-Open” Conformation
por: Meewan, Ittipat, et al.
Publicado: (2023)

Zika Virus NS3 Protease Pharmacophore Anchor Model and Drug Discovery
por: Pathak, Nikhil, et al.
Publicado: (2020)

Phosphonate inhibitors of West Nile virus NS2B/NS3 protease
por: Skoreński, Marcin, et al.
Publicado: (2018)

Interactions of the protease inhibitor, ritonavir, with common anesthesia drugs
por: Svedmyr, Anders, et al.
Publicado: (2022)

Zika Virus Targeting by Screening Inhibitors against NS2B/NS3 Protease
por: Choudhry, Hani, et al.
Publicado: (2019)

Development of NS2B-NS3 protease inhibitor that impairs Zika virus replication()
por: Lin, Wen-Wei, et al.
Publicado: (2023)

In Vitro Evaluation of Novel Inhibitors against the NS2B-NS3 Protease of Dengue Fever Virus Type 4
por: Nguyen, Thi Thanh Hanh, et al.
Publicado: (2013)

Simeprevir for the treatment of hepatitis C virus infection
por: Izquierdo, Laure, et al.
Publicado: (2014)

In vitro susceptibility of human Blastocystis subtypes to simeprevir
por: Mossallam, Shereen F., et al.
Publicado: (2021)

Simeprevir restores the anti-Staphylococcus activity of polymyxins
por: Wu, Yuan, et al.
Publicado: (2023)

Simeprevir, daclatasvir, and sofosbuvir for hepatitis C virus‐infected patients: Long‐term follow‐up results from the open‐label, Phase II IMPACT study
por: Lawitz, Eric, et al.
Publicado: (2020)

Cardiac drug-drug interaction between HCV-NS5B pronucleotide inhibitors and amiodarone is determined by their specific diastereochemistry
por: Lagrutta, Armando, et al.
Publicado: (2017)

Pharmacophore anchor models of flaviviral NS3 proteases lead to drug repurposing for DENV infection
por: Pathak, Nikhil, et al.
Publicado: (2017)

Hepatitis C virus NS3/4A inhibitors and other drug-like compounds as covalent binders of SARS-CoV-2 main protease
por: Andi, Babak, et al.
Publicado: (2022)

Safety aspects of protease inhibitors for chronic hepatitis C: adverse events and drug-to-drug interactions
por: Teixeira, Rosângela, et al.
Publicado: (2013)

Simultaneous spectrofluorimetic determination of remdesivir and simeprevir in human plasma
por: El Sharkasy, Mona E., et al.
Publicado: (2022)

Allosteric Inhibitors of the NS3 Protease from the Hepatitis C Virus
por: Abian, Olga, et al.
Publicado: (2013)

Design of New Competitive Dengue Ns2b/Ns3 Protease Inhibitors—A Computational Approach
por: Frimayanti, Neni, et al.
Publicado: (2011)

In Silico Screening, Alanine Mutation, and DFT Approaches for Identification of NS2B/NS3 Protease Inhibitors
por: Balajee, R., et al.
Publicado: (2016)

C-Terminal Extended Hexapeptides as Potent Inhibitors of the NS2B-NS3 Protease of the ZIKA Virus
por: Pant, Suyash, et al.
Publicado: (2022)

Molecular docking study of P4-Benzoxaborolesubstituted ligands as inhibitors of HCV NS3/4A protease
por: Wadood, Abdul, et al.
Publicado: (2013)

Variability and resistance mutations in the hepatitis C virus NS3 protease in patients not treated with protease inhibitors
por: Zeminian, Luciana Bonome, et al.
Publicado: (2013)

Hepatitis C Viral NS3-4A Protease Activity Is Enhanced by the NS3 Helicase
por: Beran, Rudolf K. F., et al.
Publicado: (2008)

Synthetic bulky NS4A peptide variants bind to and inhibit HCV NS3 protease
por: El-Araby, Moustafa E., et al.
Publicado: (2020)

Hepatitis C Virus NS3/4A Protease Inhibitors: A Light at the End of the Tunnel
por: Chatel-Chaix, Laurent, et al.
Publicado: (2010)

A Cross-Sectional Study Comparing the Frequency of Drug Interactions After Adding Simeprevir- or Sofosbuvir-Containing Therapy to Medication Profiles of Hepatitis C Monoinfected Patients
por: Patel, Nimish, et al.
Publicado: (2015)

Discovery of Ganoderma lucidum triterpenoids as potential inhibitors against Dengue virus NS2B-NS3 protease
por: Bharadwaj, Shiv, et al.
Publicado: (2019)

Computational study of nitro-benzylidene phenazine as dengue virus-2 NS2B-NS3 protease inhibitor
por: Salin, Nurul Hanim, et al.
Publicado: (2022)

Protease inhibitors and their peptidomimetic derivatives as potential drugs
por: Fear, Georgie, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_q682658tt1f1bhpevqfe69d5db